Compare BioNano Genomics Inc (BNGO) vs Alliant Energy Corporation (LNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Alliant Energy Corporation — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while Alliant Energy Corporation trades at $74.63 (market cap $19.71B). The key difference: Alliant Energy Corporation is far larger — about 1493.2× BioNano Genomics Inc's market cap, and Alliant Energy Corporation pays a 2.73% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | LNT | |
|---|---|---|
Market Cap | $13.20M | $19.71B |
Sector | Health | Utilities |
52-Week High | $4.92 | $78.03 |
52-Week Low | $1.09 | $61.85 |
Enterprise Value | $15.81M | $31.43B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Alliant Energy (LNT) trades at $76.63, up 0.3% today, near the consensus price target of $76.50. The stock shows a bullish technical trend with strong moving average signals. Recent earnings have mostly beaten estimates, with Q1 2026 EPS of $0.82 exceeding expectations. The company's $13.4 billion clean energy investment plan aims to capitalize on data center demand and drive 5-7% annual earnings growth, supported by rising operating cash flow and a solid 18.58% net income margin.
LNT presents a balanced opportunity with steady utility earnings and growth initiatives, but faces risks from high capital expenditure and rising debt levels. Analyst sentiment is positive with a 52% buy rating, though the stock's valuation multiples like a P/E of 24.1 suggest limited near-term upside without significant earnings acceleration. Regulatory approvals and execution on its investment plan are critical for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →
